Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience

{ 'indexed': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T01:18:17Z', 'timestamp': 1711675097807}, 'reference-count': 17, 'publisher': 'Wiley', 'license': [ { 'start': { 'date-parts': [[2024, 3, 27]], 'date-time': '2024-03-27T00:00:00Z', 'timestamp': 1711497600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'publisher', 'award': ['82000064;81900334']}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>COVID‐19 can lead to adverse outcomes in patients ' 'with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but ' 'the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in ' 'patients with COVID‐19 and pre‐existing cardiovascular diseases. Patients with confirmed ' 'COVID‐19 and pre‐existing cardiovascular diseases are retrospectively enrolled. The primary ' 'outcome is all‐cause death during hospitalization. Overall, 351 patients are included, with a ' 'median age of 74 years, and 44% are female. 212 (60.6%) patients are severe cases. Azvudine ' 'is used in 106 (30.2%) patients and not in 245 (69.8%). 72 patients died during ' 'hospitalization. After multivariate adjustment, patients who received Azvudine a lower risk ' 'of all‐cause death (hazard ratio: 0.431; 95% confidence interval: 0.252–0.738; ' '<jats:italic>p</jats:italic>\xa0=\xa00.002) than controls. Azvudine therapy is also ' 'associated with lower risks of shock and acute kidney injury. For sensitivity analysis in the ' 'propensity score‐matched cohort (<jats:italic>n</jats:italic> = 90 for each group), there is ' 'also a significant difference in all‐cause death between the two groups (hazard ratio: 0.189; ' '95% confidence interval: 0.071–0.498; <jats:italic>p</jats:italic>\xa0&lt;\xa00.001). This ' 'study indicated that Azvudine therapy is associated with better outcomes in COVID‐19 patients ' 'with pre‐existing cardiovascular diseases.</jats:p>', 'DOI': '10.1002/advs.202306050', 'type': 'journal-article', 'created': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T05:40:33Z', 'timestamp': 1711604433000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, ' 'Real‐World Experience', 'prefix': '10.1002', 'author': [ { 'given': 'Liu', 'family': 'Wu', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}, { 'given': 'Zhong‐Han', 'family': 'He', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}, { 'given': 'Ling', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}, { 'given': 'Xin', 'family': 'Guo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}, { 'given': 'Xu‐Yong', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}, { 'given': 'Hong‐Da', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [ { 'name': 'State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, ' 'National Center for Cardiovascular Diseases Chinese Academy of ' 'Medical Sciences &amp; Peking Union Medical College Beijing ' '100037 China'}]}, { 'given': 'Man‐Hua', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cardiology, The Central Hospital of Wuhan, Tongji ' 'Medical College Huazhong University of Science and Technology ' 'Wuhan 430014 China'}]}], 'member': '311', 'published-online': {'date-parts': [[2024, 3, 27]]}, 'reference': [ { 'key': 'e_1_2_10_1_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30183-5'}, { 'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(23)01003-6'}, { 'key': 'e_1_2_10_3_1', 'volume': '381', 'author': 'Wenham C.', 'year': '2023', 'journal-title': 'BMJ Clin. Res. Ed.'}, {'key': 'e_1_2_10_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.p1041'}, {'key': 'e_1_2_10_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.35772/ghm.2022.01063'}, { 'key': 'e_1_2_10_6_1', 'unstructured': 'Prevention CCFDCa The National COVID‐19 Infection ' 'Status.https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202306/t20230611_266656.htm.2023. ' 'June.'}, { 'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejmech.2023.115503'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/advs.202001435'}, {'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-021-00835-6'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.28756'}, { 'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2023.101981'}, { 'key': 'e_1_2_10_12_1', 'unstructured': 'China NHCo New coronavirus pneumonia prevention and control program (the ' 'tenth ' 'edition).http://www.nhc.gov.cn/xcs/zhengcwj/202301/bdc1ff75feb94934ae1dade176d30936.shtml.2023. ' 'January.'}, { 'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-020-00351-z'}, { 'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.xinn.2022.100321'}, { 'key': 'e_1_2_10_15_1', 'first-page': '27', 'volume': '24', 'author': 'Dian Y.', 'year': '2023', 'journal-title': 'J Infect.'}, { 'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2021.01.009'}, { 'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(22)00101-5'}], 'container-title': 'Advanced Science', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202306050', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T05:40:41Z', 'timestamp': 1711604441000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/advs.202306050'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 3, 27]]}, 'references-count': 17, 'alternative-id': ['10.1002/advs.202306050'], 'URL': 'http://dx.doi.org/10.1002/advs.202306050', 'relation': {}, 'ISSN': ['2198-3844', '2198-3844'], 'subject': [ 'General Physics and Astronomy', 'General Engineering', 'Biochemistry, Genetics and Molecular Biology (miscellaneous)', 'General Materials Science', 'General Chemical Engineering', 'Medicine (miscellaneous)'], 'container-title-short': 'Advanced Science', 'published': {'date-parts': [[2024, 3, 27]]}, 'assertion': [ { 'value': '2023-08-25', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-03-27', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}